---
title: "Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection | ADTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289053723.md"
description: "Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection | ADTX Stock News"
datetime: "2026-06-08T04:15:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289053723.md)
  - [en](https://longbridge.com/en/news/289053723.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289053723.md)
---

# Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection | ADTX Stock News

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection | ADTX Stock News

### Related Stocks

- [ADTX.US](https://longbridge.com/en/quote/ADTX.US.md)

## Related News & Research

- [Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million | ADTX Stock News](https://longbridge.com/en/news/289184727.md)
- [Why Anthropic's 'safe' Mythos-class model won't answer questions about cancer](https://longbridge.com/en/news/289277338.md)
- [AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 | ABBV Stock News](https://longbridge.com/en/news/289051772.md)
- [Can Pfizer's dividend survive the patent cliff? This $10.5 billion cancer bet could hold the answer.](https://longbridge.com/en/news/288938490.md)
- [This AI Tool Could Spot Cancer Years Before Diagnosis— And The FDA Is Taking A Look](https://longbridge.com/en/news/289192227.md)